Serveur d'exploration sur la rapamycine et les champignons

Attention, ce site est en cours de développement !
Attention, site généré par des moyens informatiques à partir de corpus bruts.
Les informations ne sont donc pas validées.

Targeting T-cell senescence and cytokine storm with rapamycin to prevent severe progression in COVID-19.

Identifieur interne : 000032 ( Main/Exploration ); précédent : 000031; suivant : 000033

Targeting T-cell senescence and cytokine storm with rapamycin to prevent severe progression in COVID-19.

Auteurs : Loukman Omarjee [France] ; Anne Janin [France] ; Frédérique Perrot [France] ; Bruno Laviolle [France] ; Olivier Meilhac [France] ; Guillaume Mahe [France]

Source :

RBID : pubmed:32405269

Descripteurs français

English descriptors


DOI: 10.1016/j.clim.2020.108464
PubMed: 32405269
PubMed Central: PMC7217787


Affiliations:


Links toward previous steps (curation, corpus...)


Le document en format XML

<record>
<TEI>
<teiHeader>
<fileDesc>
<titleStmt>
<title xml:lang="en">Targeting T-cell senescence and cytokine storm with rapamycin to prevent severe progression in COVID-19.</title>
<author>
<name sortKey="Omarjee, Loukman" sort="Omarjee, Loukman" uniqKey="Omarjee L" first="Loukman" last="Omarjee">Loukman Omarjee</name>
<affiliation wicri:level="3">
<nlm:affiliation>Inserm, NuMeCan Institute (UMR INSERM 1241), Rennes F-35033, France; Univ Rennes, CHU Rennes, INSERM, CIC1414, Clinical Immunology and Vascular Medicine, Rennes F-35033, France. Electronic address: loukman.omarjee@chu-rennes.fr.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Inserm, NuMeCan Institute (UMR INSERM 1241), Rennes F-35033, France; Univ Rennes, CHU Rennes, INSERM, CIC1414, Clinical Immunology and Vascular Medicine, Rennes F-35033</wicri:regionArea>
<placeName>
<region type="region" nuts="2">Région Bretagne</region>
</placeName>
</affiliation>
</author>
<author>
<name sortKey="Janin, Anne" sort="Janin, Anne" uniqKey="Janin A" first="Anne" last="Janin">Anne Janin</name>
<affiliation wicri:level="3">
<nlm:affiliation>Inserm, (U942), Paris Diderot University, Sorbonne Paris Cité, Paris F-75018, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Inserm, (U942), Paris Diderot University, Sorbonne Paris Cité, Paris F-75018</wicri:regionArea>
<placeName>
<region type="region" nuts="2">Île-de-France</region>
</placeName>
</affiliation>
</author>
<author>
<name sortKey="Perrot, Frederique" sort="Perrot, Frederique" uniqKey="Perrot F" first="Frédérique" last="Perrot">Frédérique Perrot</name>
<affiliation wicri:level="3">
<nlm:affiliation>Cellular and Molecular Biology Consultant, Rennes F-35033, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Cellular and Molecular Biology Consultant, Rennes F-35033</wicri:regionArea>
<placeName>
<region type="region" nuts="2">Région Bretagne</region>
</placeName>
</affiliation>
</author>
<author>
<name sortKey="Laviolle, Bruno" sort="Laviolle, Bruno" uniqKey="Laviolle B" first="Bruno" last="Laviolle">Bruno Laviolle</name>
<affiliation wicri:level="3">
<nlm:affiliation>Inserm, Clinical Investigation Center 1414, Univ Rennes, CHU Rennes, Rennes F-35033, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Inserm, Clinical Investigation Center 1414, Univ Rennes, CHU Rennes, Rennes F-35033</wicri:regionArea>
<placeName>
<region type="region" nuts="2">Région Bretagne</region>
</placeName>
</affiliation>
</author>
<author>
<name sortKey="Meilhac, Olivier" sort="Meilhac, Olivier" uniqKey="Meilhac O" first="Olivier" last="Meilhac">Olivier Meilhac</name>
<affiliation wicri:level="3">
<nlm:affiliation>Reunion Island University, INSERM U1188, Diabetes atherothrombosis Réunion Indian Ocean (DéTROI), CYROI Plateform, Sainte-Clotilde F-97490, France; CHU de La Réunion, Saint-Pierre F- 97448, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Reunion Island University, INSERM U1188, Diabetes atherothrombosis Réunion Indian Ocean (DéTROI), CYROI Plateform, Sainte-Clotilde F-97490, France; CHU de La Réunion, Saint-Pierre F- 97448</wicri:regionArea>
<placeName>
<region type="region" nuts="2">La Réunion</region>
</placeName>
</affiliation>
</author>
<author>
<name sortKey="Mahe, Guillaume" sort="Mahe, Guillaume" uniqKey="Mahe G" first="Guillaume" last="Mahe">Guillaume Mahe</name>
<affiliation wicri:level="3">
<nlm:affiliation>Inserm, Clinical Investigation Center 1414, Univ Rennes, CHU Rennes, Rennes F-35033, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Inserm, Clinical Investigation Center 1414, Univ Rennes, CHU Rennes, Rennes F-35033</wicri:regionArea>
<placeName>
<region type="region" nuts="2">Région Bretagne</region>
</placeName>
</affiliation>
</author>
</titleStmt>
<publicationStmt>
<idno type="wicri:source">PubMed</idno>
<date when="2020">2020</date>
<idno type="RBID">pubmed:32405269</idno>
<idno type="pmid">32405269</idno>
<idno type="doi">10.1016/j.clim.2020.108464</idno>
<idno type="pmc">PMC7217787</idno>
<idno type="wicri:Area/Main/Corpus">000075</idno>
<idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">000075</idno>
<idno type="wicri:Area/Main/Curation">000075</idno>
<idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Curation">000075</idno>
<idno type="wicri:Area/Main/Exploration">000075</idno>
</publicationStmt>
<sourceDesc>
<biblStruct>
<analytic>
<title xml:lang="en">Targeting T-cell senescence and cytokine storm with rapamycin to prevent severe progression in COVID-19.</title>
<author>
<name sortKey="Omarjee, Loukman" sort="Omarjee, Loukman" uniqKey="Omarjee L" first="Loukman" last="Omarjee">Loukman Omarjee</name>
<affiliation wicri:level="3">
<nlm:affiliation>Inserm, NuMeCan Institute (UMR INSERM 1241), Rennes F-35033, France; Univ Rennes, CHU Rennes, INSERM, CIC1414, Clinical Immunology and Vascular Medicine, Rennes F-35033, France. Electronic address: loukman.omarjee@chu-rennes.fr.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Inserm, NuMeCan Institute (UMR INSERM 1241), Rennes F-35033, France; Univ Rennes, CHU Rennes, INSERM, CIC1414, Clinical Immunology and Vascular Medicine, Rennes F-35033</wicri:regionArea>
<placeName>
<region type="region" nuts="2">Région Bretagne</region>
</placeName>
</affiliation>
</author>
<author>
<name sortKey="Janin, Anne" sort="Janin, Anne" uniqKey="Janin A" first="Anne" last="Janin">Anne Janin</name>
<affiliation wicri:level="3">
<nlm:affiliation>Inserm, (U942), Paris Diderot University, Sorbonne Paris Cité, Paris F-75018, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Inserm, (U942), Paris Diderot University, Sorbonne Paris Cité, Paris F-75018</wicri:regionArea>
<placeName>
<region type="region" nuts="2">Île-de-France</region>
</placeName>
</affiliation>
</author>
<author>
<name sortKey="Perrot, Frederique" sort="Perrot, Frederique" uniqKey="Perrot F" first="Frédérique" last="Perrot">Frédérique Perrot</name>
<affiliation wicri:level="3">
<nlm:affiliation>Cellular and Molecular Biology Consultant, Rennes F-35033, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Cellular and Molecular Biology Consultant, Rennes F-35033</wicri:regionArea>
<placeName>
<region type="region" nuts="2">Région Bretagne</region>
</placeName>
</affiliation>
</author>
<author>
<name sortKey="Laviolle, Bruno" sort="Laviolle, Bruno" uniqKey="Laviolle B" first="Bruno" last="Laviolle">Bruno Laviolle</name>
<affiliation wicri:level="3">
<nlm:affiliation>Inserm, Clinical Investigation Center 1414, Univ Rennes, CHU Rennes, Rennes F-35033, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Inserm, Clinical Investigation Center 1414, Univ Rennes, CHU Rennes, Rennes F-35033</wicri:regionArea>
<placeName>
<region type="region" nuts="2">Région Bretagne</region>
</placeName>
</affiliation>
</author>
<author>
<name sortKey="Meilhac, Olivier" sort="Meilhac, Olivier" uniqKey="Meilhac O" first="Olivier" last="Meilhac">Olivier Meilhac</name>
<affiliation wicri:level="3">
<nlm:affiliation>Reunion Island University, INSERM U1188, Diabetes atherothrombosis Réunion Indian Ocean (DéTROI), CYROI Plateform, Sainte-Clotilde F-97490, France; CHU de La Réunion, Saint-Pierre F- 97448, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Reunion Island University, INSERM U1188, Diabetes atherothrombosis Réunion Indian Ocean (DéTROI), CYROI Plateform, Sainte-Clotilde F-97490, France; CHU de La Réunion, Saint-Pierre F- 97448</wicri:regionArea>
<placeName>
<region type="region" nuts="2">La Réunion</region>
</placeName>
</affiliation>
</author>
<author>
<name sortKey="Mahe, Guillaume" sort="Mahe, Guillaume" uniqKey="Mahe G" first="Guillaume" last="Mahe">Guillaume Mahe</name>
<affiliation wicri:level="3">
<nlm:affiliation>Inserm, Clinical Investigation Center 1414, Univ Rennes, CHU Rennes, Rennes F-35033, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Inserm, Clinical Investigation Center 1414, Univ Rennes, CHU Rennes, Rennes F-35033</wicri:regionArea>
<placeName>
<region type="region" nuts="2">Région Bretagne</region>
</placeName>
</affiliation>
</author>
</analytic>
<series>
<title level="j">Clinical immunology (Orlando, Fla.)</title>
<idno type="eISSN">1521-7035</idno>
<imprint>
<date when="2020" type="published">2020</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc>
<textClass>
<keywords scheme="KwdEn" xml:lang="en">
<term>Betacoronavirus (drug effects)</term>
<term>Betacoronavirus (immunology)</term>
<term>Betacoronavirus (pathogenicity)</term>
<term>Coronavirus Infections (drug therapy)</term>
<term>Coronavirus Infections (epidemiology)</term>
<term>Coronavirus Infections (immunology)</term>
<term>Coronavirus Infections (virology)</term>
<term>Cytokine Release Syndrome (etiology)</term>
<term>Cytokine Release Syndrome (immunology)</term>
<term>Cytokine Release Syndrome (pathology)</term>
<term>Cytokine Release Syndrome (prevention & control)</term>
<term>Cytokines (antagonists & inhibitors)</term>
<term>Cytokines (genetics)</term>
<term>Cytokines (immunology)</term>
<term>Disease Progression (MeSH)</term>
<term>Gene Expression Regulation (MeSH)</term>
<term>Humans (MeSH)</term>
<term>Immunity, Innate (drug effects)</term>
<term>Immunologic Factors (therapeutic use)</term>
<term>Molecular Targeted Therapy (methods)</term>
<term>Pandemics (MeSH)</term>
<term>Pneumonia, Viral (drug therapy)</term>
<term>Pneumonia, Viral (epidemiology)</term>
<term>Pneumonia, Viral (immunology)</term>
<term>Pneumonia, Viral (virology)</term>
<term>Sirolimus (therapeutic use)</term>
<term>T-Lymphocytes (drug effects)</term>
<term>T-Lymphocytes (immunology)</term>
<term>T-Lymphocytes (virology)</term>
</keywords>
<keywords scheme="KwdFr" xml:lang="fr">
<term>Betacoronavirus (effets des médicaments et des substances chimiques)</term>
<term>Betacoronavirus (immunologie)</term>
<term>Betacoronavirus (pathogénicité)</term>
<term>Cytokines (antagonistes et inhibiteurs)</term>
<term>Cytokines (génétique)</term>
<term>Cytokines (immunologie)</term>
<term>Facteurs immunologiques (usage thérapeutique)</term>
<term>Humains (MeSH)</term>
<term>Immunité innée (effets des médicaments et des substances chimiques)</term>
<term>Infections à coronavirus (immunologie)</term>
<term>Infections à coronavirus (traitement médicamenteux)</term>
<term>Infections à coronavirus (virologie)</term>
<term>Infections à coronavirus (épidémiologie)</term>
<term>Lymphocytes T (effets des médicaments et des substances chimiques)</term>
<term>Lymphocytes T (immunologie)</term>
<term>Lymphocytes T (virologie)</term>
<term>Pandémies (MeSH)</term>
<term>Pneumopathie virale (immunologie)</term>
<term>Pneumopathie virale (traitement médicamenteux)</term>
<term>Pneumopathie virale (virologie)</term>
<term>Pneumopathie virale (épidémiologie)</term>
<term>Régulation de l'expression des gènes (MeSH)</term>
<term>Sirolimus (usage thérapeutique)</term>
<term>Thérapie moléculaire ciblée (méthodes)</term>
<term>Évolution de la maladie (MeSH)</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="antagonists & inhibitors" xml:lang="en">
<term>Cytokines</term>
</keywords>
<keywords scheme="MESH" qualifier="antagonistes et inhibiteurs" xml:lang="fr">
<term>Cytokines</term>
</keywords>
<keywords scheme="MESH" qualifier="drug effects" xml:lang="en">
<term>Betacoronavirus</term>
<term>Immunity, Innate</term>
<term>T-Lymphocytes</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en">
<term>Coronavirus Infections</term>
<term>Pneumonia, Viral</term>
</keywords>
<keywords scheme="MESH" qualifier="effets des médicaments et des substances chimiques" xml:lang="fr">
<term>Betacoronavirus</term>
<term>Immunité innée</term>
<term>Lymphocytes T</term>
</keywords>
<keywords scheme="MESH" qualifier="epidemiology" xml:lang="en">
<term>Coronavirus Infections</term>
<term>Pneumonia, Viral</term>
</keywords>
<keywords scheme="MESH" qualifier="etiology" xml:lang="en">
<term>Cytokine Release Syndrome</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="genetics" xml:lang="en">
<term>Cytokines</term>
</keywords>
<keywords scheme="MESH" qualifier="génétique" xml:lang="fr">
<term>Cytokines</term>
</keywords>
<keywords scheme="MESH" qualifier="immunologie" xml:lang="fr">
<term>Betacoronavirus</term>
<term>Cytokines</term>
<term>Infections à coronavirus</term>
<term>Lymphocytes T</term>
<term>Pneumopathie virale</term>
</keywords>
<keywords scheme="MESH" qualifier="immunology" xml:lang="en">
<term>Betacoronavirus</term>
<term>Coronavirus Infections</term>
<term>Cytokine Release Syndrome</term>
<term>Cytokines</term>
<term>Pneumonia, Viral</term>
<term>T-Lymphocytes</term>
</keywords>
<keywords scheme="MESH" qualifier="methods" xml:lang="en">
<term>Molecular Targeted Therapy</term>
</keywords>
<keywords scheme="MESH" qualifier="méthodes" xml:lang="fr">
<term>Thérapie moléculaire ciblée</term>
</keywords>
<keywords scheme="MESH" qualifier="pathogenicity" xml:lang="en">
<term>Betacoronavirus</term>
</keywords>
<keywords scheme="MESH" qualifier="pathogénicité" xml:lang="fr">
<term>Betacoronavirus</term>
</keywords>
<keywords scheme="MESH" qualifier="pathology" xml:lang="en">
<term>Cytokine Release Syndrome</term>
</keywords>
<keywords scheme="MESH" qualifier="prevention & control" xml:lang="en">
<term>Cytokine Release Syndrome</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en">
<term>Immunologic Factors</term>
<term>Sirolimus</term>
</keywords>
<keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr">
<term>Infections à coronavirus</term>
<term>Pneumopathie virale</term>
</keywords>
<keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr">
<term>Facteurs immunologiques</term>
<term>Sirolimus</term>
</keywords>
<keywords scheme="MESH" qualifier="virologie" xml:lang="fr">
<term>Infections à coronavirus</term>
<term>Lymphocytes T</term>
<term>Pneumopathie virale</term>
</keywords>
<keywords scheme="MESH" qualifier="virology" xml:lang="en">
<term>Coronavirus Infections</term>
<term>Pneumonia, Viral</term>
<term>T-Lymphocytes</term>
</keywords>
<keywords scheme="MESH" qualifier="épidémiologie" xml:lang="fr">
<term>Infections à coronavirus</term>
<term>Pneumopathie virale</term>
</keywords>
<keywords scheme="MESH" xml:lang="en">
<term>Disease Progression</term>
<term>Gene Expression Regulation</term>
<term>Humans</term>
<term>Pandemics</term>
</keywords>
<keywords scheme="MESH" xml:lang="fr">
<term>Humains</term>
<term>Pandémies</term>
<term>Régulation de l'expression des gènes</term>
<term>Évolution de la maladie</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
</TEI>
<pubmed>
<MedlineCitation Status="MEDLINE" Owner="NLM">
<PMID Version="1">32405269</PMID>
<DateCompleted>
<Year>2020</Year>
<Month>07</Month>
<Day>13</Day>
</DateCompleted>
<DateRevised>
<Year>2020</Year>
<Month>07</Month>
<Day>13</Day>
</DateRevised>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Electronic">1521-7035</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>216</Volume>
<PubDate>
<Year>2020</Year>
<Month>07</Month>
</PubDate>
</JournalIssue>
<Title>Clinical immunology (Orlando, Fla.)</Title>
<ISOAbbreviation>Clin Immunol</ISOAbbreviation>
</Journal>
<ArticleTitle>Targeting T-cell senescence and cytokine storm with rapamycin to prevent severe progression in COVID-19.</ArticleTitle>
<Pagination>
<MedlinePgn>108464</MedlinePgn>
</Pagination>
<ELocationID EIdType="pii" ValidYN="Y">S1521-6616(20)30319-3</ELocationID>
<ELocationID EIdType="doi" ValidYN="Y">10.1016/j.clim.2020.108464</ELocationID>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Omarjee</LastName>
<ForeName>Loukman</ForeName>
<Initials>L</Initials>
<AffiliationInfo>
<Affiliation>Inserm, NuMeCan Institute (UMR INSERM 1241), Rennes F-35033, France; Univ Rennes, CHU Rennes, INSERM, CIC1414, Clinical Immunology and Vascular Medicine, Rennes F-35033, France. Electronic address: loukman.omarjee@chu-rennes.fr.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Janin</LastName>
<ForeName>Anne</ForeName>
<Initials>A</Initials>
<AffiliationInfo>
<Affiliation>Inserm, (U942), Paris Diderot University, Sorbonne Paris Cité, Paris F-75018, France.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Perrot</LastName>
<ForeName>Frédérique</ForeName>
<Initials>F</Initials>
<AffiliationInfo>
<Affiliation>Cellular and Molecular Biology Consultant, Rennes F-35033, France.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Laviolle</LastName>
<ForeName>Bruno</ForeName>
<Initials>B</Initials>
<AffiliationInfo>
<Affiliation>Inserm, Clinical Investigation Center 1414, Univ Rennes, CHU Rennes, Rennes F-35033, France.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Meilhac</LastName>
<ForeName>Olivier</ForeName>
<Initials>O</Initials>
<AffiliationInfo>
<Affiliation>Reunion Island University, INSERM U1188, Diabetes atherothrombosis Réunion Indian Ocean (DéTROI), CYROI Plateform, Sainte-Clotilde F-97490, France; CHU de La Réunion, Saint-Pierre F- 97448, France.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Mahe</LastName>
<ForeName>Guillaume</ForeName>
<Initials>G</Initials>
<AffiliationInfo>
<Affiliation>Inserm, Clinical Investigation Center 1414, Univ Rennes, CHU Rennes, Rennes F-35033, France.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType UI="D016422">Letter</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2020</Year>
<Month>05</Month>
<Day>13</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>United States</Country>
<MedlineTA>Clin Immunol</MedlineTA>
<NlmUniqueID>100883537</NlmUniqueID>
<ISSNLinking>1521-6616</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D016207">Cytokines</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D007155">Immunologic Factors</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>W36ZG6FT64</RegistryNumber>
<NameOfSubstance UI="D020123">Sirolimus</NameOfSubstance>
</Chemical>
</ChemicalList>
<SupplMeshList>
<SupplMeshName Type="Disease" UI="C000657245">COVID-19</SupplMeshName>
<SupplMeshName Type="Organism" UI="C000656484">severe acute respiratory syndrome coronavirus 2</SupplMeshName>
</SupplMeshList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName UI="D000073640" MajorTopicYN="N">Betacoronavirus</DescriptorName>
<QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
<QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
<QualifierName UI="Q000472" MajorTopicYN="N">pathogenicity</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D018352" MajorTopicYN="N">Coronavirus Infections</DescriptorName>
<QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
<QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName>
<QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
<QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D000080424" MajorTopicYN="N">Cytokine Release Syndrome</DescriptorName>
<QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName>
<QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
<QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
<QualifierName UI="Q000517" MajorTopicYN="Y">prevention & control</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D016207" MajorTopicYN="N">Cytokines</DescriptorName>
<QualifierName UI="Q000037" MajorTopicYN="Y">antagonists & inhibitors</QualifierName>
<QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
<QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D018450" MajorTopicYN="N">Disease Progression</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D005786" MajorTopicYN="N">Gene Expression Regulation</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D007113" MajorTopicYN="N">Immunity, Innate</DescriptorName>
<QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D007155" MajorTopicYN="N">Immunologic Factors</DescriptorName>
<QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D058990" MajorTopicYN="N">Molecular Targeted Therapy</DescriptorName>
<QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D058873" MajorTopicYN="Y">Pandemics</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D011024" MajorTopicYN="N">Pneumonia, Viral</DescriptorName>
<QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
<QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName>
<QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
<QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D020123" MajorTopicYN="N">Sirolimus</DescriptorName>
<QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D013601" MajorTopicYN="N">T-Lymphocytes</DescriptorName>
<QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
<QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
<QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName>
</MeshHeading>
</MeshHeadingList>
<CoiStatement>Declaration of Competing Interest All authors declare they have nothing to disclose, and no competing interests.</CoiStatement>
</MedlineCitation>
<PubmedData>
<History>
<PubMedPubDate PubStatus="received">
<Year>2020</Year>
<Month>04</Month>
<Day>23</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="revised">
<Year>2020</Year>
<Month>05</Month>
<Day>10</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="accepted">
<Year>2020</Year>
<Month>05</Month>
<Day>10</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="pubmed">
<Year>2020</Year>
<Month>5</Month>
<Day>15</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline">
<Year>2020</Year>
<Month>7</Month>
<Day>14</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="entrez">
<Year>2020</Year>
<Month>5</Month>
<Day>15</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList>
<ArticleId IdType="pubmed">32405269</ArticleId>
<ArticleId IdType="doi">10.1016/j.clim.2020.108464</ArticleId>
<ArticleId IdType="pii">S1521-6616(20)30319-3</ArticleId>
<ArticleId IdType="pmc">PMC7217787</ArticleId>
</ArticleIdList>
</PubmedData>
</pubmed>
<affiliations>
<list>
<country>
<li>France</li>
</country>
<region>
<li>La Réunion</li>
<li>Région Bretagne</li>
<li>Île-de-France</li>
</region>
</list>
<tree>
<country name="France">
<region name="Région Bretagne">
<name sortKey="Omarjee, Loukman" sort="Omarjee, Loukman" uniqKey="Omarjee L" first="Loukman" last="Omarjee">Loukman Omarjee</name>
</region>
<name sortKey="Janin, Anne" sort="Janin, Anne" uniqKey="Janin A" first="Anne" last="Janin">Anne Janin</name>
<name sortKey="Laviolle, Bruno" sort="Laviolle, Bruno" uniqKey="Laviolle B" first="Bruno" last="Laviolle">Bruno Laviolle</name>
<name sortKey="Mahe, Guillaume" sort="Mahe, Guillaume" uniqKey="Mahe G" first="Guillaume" last="Mahe">Guillaume Mahe</name>
<name sortKey="Meilhac, Olivier" sort="Meilhac, Olivier" uniqKey="Meilhac O" first="Olivier" last="Meilhac">Olivier Meilhac</name>
<name sortKey="Perrot, Frederique" sort="Perrot, Frederique" uniqKey="Perrot F" first="Frédérique" last="Perrot">Frédérique Perrot</name>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Bois/explor/RapamycinFungusV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000032 | SxmlIndent | more

Ou

HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000032 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Bois
   |area=    RapamycinFungusV1
   |flux=    Main
   |étape=   Exploration
   |type=    RBID
   |clé=     pubmed:32405269
   |texte=   Targeting T-cell senescence and cytokine storm with rapamycin to prevent severe progression in COVID-19.
}}

Pour générer des pages wiki

HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i   -Sk "pubmed:32405269" \
       | HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd   \
       | NlmPubMed2Wicri -a RapamycinFungusV1 

Wicri

This area was generated with Dilib version V0.6.38.
Data generation: Thu Nov 19 21:55:41 2020. Site generation: Thu Nov 19 22:00:39 2020